Evaluation of hormone receptor status (ER/PR/HER2-neu) in breast cancer in Pakistan

Journal of the Pakistan Medical Association

Volumn 65, Issue 7, 2015, Pages 747-752

  Pervaiz, Fahad ^a   Rehmani, Sahrish ^a   Majid, Sana ^a   Anwar, Hina ^a  

^a THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

Author keywords

Breast cancer; Chemotherapy; HER2 neu; Oestrogen

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; LETROZOLE; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOMA; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; METASTASIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VOLUME; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; PAKISTAN; PATHOLOGY; UNILATERAL BREAST NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PAKISTAN; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; UNILATERAL BREAST NEOPLASMS; YOUNG ADULT;

EID: 84934774866     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. American Cancer Society. Cancer Facts and Figures 2004; 3: 10.
2. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast cancer-histopathological and prognostic considerations. Br J Cancer 1997; 75: 1318-23.
3. Shannon C, Smith IE. Breast cancer in adolescents and young women. Eur J Cancer 2003; 39: 2632-42.
4. Carey KA, David SH, Gloria B, Chaitanya RA, John AF, Yi Zhang, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26: 3324-30.
5. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in young women (<40 Years) compared with older women is attributed to poorer survival in early stage disease. J Am Coll Surg 2009; 208: 341-7.
6. Nagi S E, Muhieddine S, Mazen KK, Maya C, Ziad KS, Fady BG, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006; 6: 194.
7. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of Axillary Lymph Node Metastasis in Primary Breast Cancer. J Clin Oncol 1999; 17: 2334-40.
8. Brian EH, Leslie B, Ronald K. Hormones and the Etiology of Cancer. In: Robert CB, Donald WK, Raphael EP, Ralph RW, James FH, Emil F, eds. Holland-Frei Cancer Medicine. 5th ed. Hamilton, Ontario: B.C. Decker, 2000.
9. Henderson BE, Ross RK, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1988;48:246-53.
10. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res 1982; 42: 3232-9.
11. Key TJ, Pike MC. The role of oestrogens and progestogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988; 24: 29-43.
12. Ferguson DJ, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br J Cancer 1981; 44: 177-81.
13. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 1993; 259: 633-8.
14. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076-87.
15. Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E, et al. Hormone receptors as prognostic factors in female breast cancer. Ann Med 1991; 23: 643-8.
16. Lethaby AE, Mason BH, Harvey VJ, Holdaway IM. Survival of women with node negative breast cancer in the Auckland region. N Z Med J 1996; 109: 330-3.
17. WHO. Histological typing of breast tumours, 2nd edn, international histological classification of tumours no. 2. WHO, Geneva; 1981.
18. Bloom HJG, Richardson WW. Histological Grading and prognosis in breast cancer. Br J Cancer 1957; 11: 359-77.
19. Pegoraro RJ, Karnan V, Nirmul D, Joubert SM. Estrogen and progesterone receptors in breast cancer among women of different racial groups. Cancer Res 1986; 46: 2117-20.
20. Avima MR, Flora L, Yochanan W, Abraham G, Esther ARN, Angela C. Estrogen and progesterone receptors in breast cancer patients: Epidemiologic characteristics and survival differences. Cancer 1989; 64: 196-202.
21. Susan MG, Josée D, Peter G, Susan C, David PW. Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women: An analysis of 13,239 cases. Cancer 1996;77:1465-71.
22. Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat 2002;73:45-59.
23. Utah, Atlanta. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-7.
24. Foster RS. The biologic and clinical significance of lymphatic metastases in breast cancer. Surg Oncol Clin N Am 1996;5:79-104.
25. Rodríguez-Cuevas S, Macías CG, Franceschi D, Labastida S. Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer 2001;91:863-8.
26. Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr 1994;16: 69-77.
27. Sughayer, MaherA, Maha M, Al-Khawaja, Massarweh S, Mahmoud Al-Masri. Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Pathol Oncol Res 2006;12:83-6.